Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam
Drugs in R&D · 2026-03 · 26 (1) · 51-70
DOI: 10.1007/s40268-026-00540-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs in R&D, online erschienen am 11.03.2026. Verfasst von Yang Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Wuhan University of Science and Technology, Wuhan, 430065, China. Hauptthemen laut MEDLINE: Piroxicam, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chutian Elite Program of Hubei Province for Health Professionals, Hunan Provincial Natural Science Foundation (Science and Medicine Joint Fund), Wuhan Natural Science Foundation Exploration Program.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Lornoxicam (LOX) is a nonsteroidal anti-inflammatory drug used for pain management but requires frequent dosing due to its short half-life. This study aimed to develop a biphasic-release multiple-unit tablet (MUT) to achieve rapid and sustained LOX release with dose flexibility. METHODS: LOX-loaded extended-release (ER) pellets were prepared by fluidized-bed coating of microcrystalline cellulose cores and optimized using a Box-Behnken design. The pellets were coated with Eudragit® RL/RS and combined with an immediate-release (IR) component to form MUTs by conventional tableting. Pellets and tablets were evaluated for physicochemical properties and in vitro drug release. RESULTS: Optimized ER pellets showed high drug-loading efficiency (92.2 ± 3%) and good mechanical properties. Drug release from ER pellets was best described by the Korsmeyer-Peppas model, indicating Fickian diffusion. The MUTs exhibited an initial LOX release of approximately 38%, followed by sustained release for 24 h, with > 90% cumulative release. Split tablets demonstrated release profiles comparable to intact tablets (f2 > 50). CONCLUSION: The developed biphasic-release MUTs provide rapid onset, sustained LOX delivery, and reliable dose flexibility, representing a promising oral formulation for LOX therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Wuhan University of Science and Technology, Wuhan, 430065, China.
- Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, 430070, China.
- Department of Pharmacy, Zhuzhou Central Hospital, Zhuzhou, 412000, China.
- School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, 442000, China.
- Department of Pharmacy, General Hospital of Central Theater Command, Wuhan, 430070, China. 1056873163@163.com.
- School of Medicine, Wuhan University of Science and Technology, Wuhan, 430065, China. xxy5727035@163.com.
Förderung
- Chutian Elite Program of Hubei Province for Health Professionals
- Hunan Provincial Natural Science Foundation (Science and Medicine Joint Fund)
- Wuhan Natural Science Foundation Exploration Program
Zitieren
APA
Liu, Y., Shi, Q. Z., Wang, Y., Long, Z. C., Han, M., Zeng, Y., Xie, X. Y., & Liu, H. (2026). Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam. Drugs in R&D, 26(1), 51-70. https://doi.org/10.1007/s40268-026-00540-1
Vancouver
Liu Y, Shi QZ, Wang Y, Long ZC, Han M, Zeng Y, et al. Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam. Drugs in R&D. 2026;26(1):51-70. doi:10.1007/s40268-026-00540-1
BibTeX
@article{Liu2026,
author = {Liu, Yang and Shi, Qiong-Zhi and Wang, Yanchen and Long, Ze-Chun and Han, Man and Zeng, Yuan and Xie, Xiang-Yang and Liu, Hui},
title = {Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam},
journal = {Drugs in R&D},
year = {2026},
volume = {26},
number = {1},
pages = {51--70},
doi = {10.1007/s40268-026-00540-1}
}
EUVIMED